Fuziderm-B cream 15 g. tube


Manufacturer: Jordan

Fuzikutan cream is indicated for the local treatment of infectious skin diseases caused by bacteria that are sensitive to the action of fusidic acid (see the section “Pharmacodynamics”). The cream is used for the treatment of wet skin diseases.



Fuziderm-B Storage:

active substances: fusidic acid and betamethasone;

1 g of cream contains 20 mg of fusidic acid and 1 mg of betamethasone (in the form of valerate);

Excipients: white soft paraffin, cetostearyl alcohol, polyethylene glycol 1000 cetostearyl ether, mineral light oil, methylparaben (E 218), propylparaben (E 216), sodium citrate, propylene glycol, purified water.

Fuziderm-B Dosage form.


Basic physical and chemical properties: homogeneous white cream.

Fuziderm-B Pharmacotherapeutic group.

Corticosteroids for use in dermatology. Corticosteroids in combination with antibiotics. Betamethasone and antibiotics.

ATX code D07C C01.

Pharmacological properties.

Fusiderm®-B is a combined drug that combines the powerful antibacterial action of fusidic acid and the local anti-inflammatory action of betamethasone.


Fusidic acid is a natural antibiotic formed during the growth of Fusidium coccineum. Fusidic acid disrupts the protein synthesis of microbial cells, depending on the dose acts bacteriostatically or bactericidal. The drug has a powerful antibacterial effect on a wide range of gram-positive microorganisms – Staphylococcus spp., Streptococcus spp., Corynebacterium minutissimum, Propionibacterium acnes – including on staphylococci resistant to penicillin, streptomycin, chloramphenicol, erythromycin and other antibiotics. Fusiderm®-B has the ability to act through intact skin. When applied topically, fusidic acid is active against Corynebacteria spp., Neisseria spp., Clostridia spr., Bacteroides spp.

Betamethasone is a glucocorticosteroid for use in dermatology. When applied topically has a pronounced anti-inflammatory, antipyretic, anti-allergic and anti-exudative effect, reduces itching and collagen synthesis in the skin.


When applied topically, systemic absorption is negligible.

There are no data that characterize the pharmacokinetics of Fusiderm®-B cream when applied topically.

However, some in vitro studies suggest that fusidic acid can penetrate intact human skin. The degree of absorption depends on the duration of exposure to fusidic acid and the condition of the skin. Fusidic acid is excreted mainly in the bile and to a lesser extent in the urine.

Betamethasone is absorbed after topical application. The degree of absorption depends on the application site and the condition of the skin. Betamethasone is metabolised mainly by the liver and to a lesser extent by the kidneys. Inactive metabolites are excreted mostly in the urine.

Clinical characteristics.


Treatment of eczematous dermatoses in the presence of bacterial infection or with a high probability, such as: atopic eczema, childhood eczema, discoid eczema, congestive eczema, contact eczema, seborrheic eczema, herpes zoster, psoriasis (except for the common form of psoriasis) discoid lupus erythematosus.


Viral infections, including post-vaccination reactions and chickenpox, viral skin infections (eg herpes simplex, shingles), pink acne, rosacea (perioral) dermatitis, bacterial dermatoses, including tuberculosis and syphilis, skin diseases, fungus parts of the head, skin and soft tissue infections that are not sensitive to fusidic acid, such as Pseudomonas aeruginosa. Hypersensitivity to any components of the drug.

Do not allow the drug to get into the eyes or mucous membranes.

The use of cream under occlusive dressings (plaster) is not recommended.

Fusiderm®-B cream should not be used in the first trimester of pregnancy (see section “Use during pregnancy or breastfeeding”).